Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Income: 2009-2024

Historic Net Income for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $23.4 million.

  • Tg Therapeutics' Net Income rose 10006.23% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 3212.81%. This contributed to the annual value of $23.4 million for FY2024, which is 84.52% up from last year.
  • Per Tg Therapeutics' latest filing, its Net Income stood at $23.4 million for FY2024, which was up 84.52% from $12.7 million recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Net Income peaked at $23.4 million during FY2024, and registered a low of -$348.1 million during FY2021.
  • For the 3-year period, Tg Therapeutics' Net Income averaged around -$62.6 million, with its median value being $12.7 million (2023).
  • As far as peak fluctuations go, Tg Therapeutics' Net Income plummeted by 60.56% in 2020, and later surged by 105.66% in 2023.
  • Yearly analysis of 5 years shows Tg Therapeutics' Net Income stood at -$279.9 million in 2020, then dropped by 24.36% to -$348.1 million in 2021, then surged by 35.70% to -$223.8 million in 2022, then spiked by 105.66% to $12.7 million in 2023, then soared by 84.52% to $23.4 million in 2024.